milvexian

Advertisement

cGxPJobs Banner

Milvexian Phase 3 ACS Trial Discontinued After Interim Review

Dateline: November 17, 2025 — Princeton, N.J.In a significant development for anticoagulant therapy, Milvexian (also known as Librexia) —...

By cGxPwire Editor
November 16, 2025

Read More

Bristol Myers Squibb Unveils New Long-Term and Real-World Data for Camzyos at AHA 2025

Princeton, N.J., November 4, 2025 – Bristol Myers Squibb (NYSE: BMY) announced a major scientific milestone with the presentation...

By cGxPwire Editor
November 4, 2025

Read More

Advertisement

cGxPJobs

Directory